Therapy News and Research

RSS

Expression of particular estrogen receptor can reinstate lost memory function

The hormone estrogen helps protect memory and promote a healthy brain, but this effect wanes as women age, and even estrogen replacement therapy stops working in humans after age 65. Now researchers at University of Florida Health have used gene therapy in a rat model to show that the expression of a particular receptor can reinstate lost memory function.

9 Dec 2015

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Rising Tide Foundation for Clinical Cancer Research, an international private foundation based in Switzerland, has awarded a US $800,000 grant to be released over two years for the ASCOLT study conducted by Dr John Chia, Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore.

9 Dec 2015

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report published in the New England Journal of Medicine describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.

9 Dec 2015

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

8 Dec 2015

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

Testing for developmental delay through an app? An interview with Dr. Clara Lajonchere

Cognoa's app helps every parent find out if their child’s development is on track and, if not, get their child the right help as early as possible.

8 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

Researchers find new significant link between NPM protein and development of AML

A team of researchers from the National University of Singapore has found a new significant correlation between the protein nucleophosmin (NPM) and the development of an aggressive form of blood cancer called acute myeloid leukemia (AML).

8 Dec 2015

New technology may facilitate early detection of sickle cell disease for infants in developing countries

Researchers from Seidman Cancer Center at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine presented new research findings this weekend at the 57th Annual Meeting of the American Society of Hematology in Orlando.

8 Dec 2015

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease in the years that followed than those who didn't undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown.

8 Dec 2015

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult' treatment protocols, report Dana-Farber Cancer Institute scientists.

8 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.

8 Dec 2015

ESCMID’s EUCAST plays key role in defining antimicrobial resistance in Europe and globally

The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organization that pursues science, explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – is currently researching the new critical breakpoints for antimicrobial agents in clinical development through its European Committee on Antimicrobial Susceptibility Testing (EUCAST).

8 Dec 2015

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

A new analysis indicates that certain characteristics may increase a breast cancer survivor’s risk of developing leukemia after undergoing chemotherapy and/or radiation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings are a first step toward finding ways to prevent this serious and potentially life-threatening treatment-related complication.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

8 Dec 2015

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.

7 Dec 2015

Therapy News and Research

Expression of particular estrogen receptor can reinstate lost memory function

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Treatment with antiplatelet therapy does not reduce pain crises in children with sickle cell disease

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Kanuma approved as first treatment for patients with LAL deficiency

Testing for developmental delay through an app? An interview with Dr. Clara Lajonchere

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

Researchers find new significant link between NPM protein and development of AML

New technology may facilitate early detection of sickle cell disease for infants in developing countries

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Researchers discover 'triple attack' technique to target liver cancer tumors

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

ESCMID’s EUCAST plays key role in defining antimicrobial resistance in Europe and globally

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News